Pfizer Inc (Pfizer) discovers, develops, manufactures, and commercializes generic and branded medicines, biosimilars, vaccines, and internal medicines. The company's drugs are indicated for the treatment of cancer, inflammation and other immune disorders and rare diseases. Its portfolio includes patented and generic drugs and active pharmaceutical ingredients (APIs).

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Pfizer’s R&D focuses on the development of novel medicines for the treatment of cancer, inflammation, immune disorders, cardiovascular diseases, metabolic diseases, and rare diseases, besides sterile injectables, anti-infectives and vaccines. Pfizer offers a diverse portfolio of medicines to address unmet needs in various rare disease conditions related to hematology, neurology, endocrinology, cardiology, and inherited metabolic diseases. Through this comprehensive approach, Pfizer intends to make a meaningful impact on the lives of patients with rare diseases. Pfizer's internal medicine sector focuses on the exploration of metabolic abnormalities that lead to the development of cardiometabolic diseases. The company actively pursues the development of potential therapies targeting such diseases, which stem from an abnormal metabolic state. By conducting research in these areas, Pfizer aims at advancing medical understanding and developing innovative approaches to address cardiometabolic diseases. Pfizer has established a growing collaboration with various pharmaceuticals to conduct research in various diseases. This collaboration aims at promoting advancements in understanding and treatment of these conditions through joint research initiatives. In FY2023, the company spent US$10,679 million on R&D, which as a percentage of revenue stood at 18.2%. It has R&D facilities in California, Massachusetts, Missouri, Connecticut, and New York in the US; and Cambridge and Sandwich in the UK. The company has a total of 112 products in the pipeline with 41 products in Phase 1 clinical trials; 34 products in Phase II clinical trials; 31 products in Phase III and late-stage clinical trials, while it filed applications for 6 pipeline products for the registration process. The company owns numerous US and foreign patents covering pharmaceutical and other products and their uses, product manufacturing processes, pharmaceutical formulations and intermediate chemical compounds used in the manufacture of its products.